Venous thrombosis in HIV infection

Laing, R. B. S.; Brettle, R P; Leen, Clifford

doi:10.1258/0956462961917410

Cited by 34 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed a trend towards a higher risk of VTE with a low CD4 count (o200 cells/mL), although the association was not statistically significant. IDU has been identified as a strong risk factor for community-acquired VTE in young adults [48,49], mainly because of the venous damage induced by the drug abuse [12,16,22]. IDU accounts for nearly 10% of all communityacquired VTE and almost 50% of episodes in patients aged 40 years [48].…”

Section: Discussionmentioning

confidence: 99%

“…Studies mainly from the pre-HAART era estimated that the overall risk of VTE in patients with HIV infection was roughly 2-10-fold higher than expected in the general population [11][12][13][14][15][16][17][18][19][20][21][22][23][24]. However, many studies were limited by small sample size [15,16,22,23] and a lack of a population-based comparison cohort [11][12][13]15,16,19,[21][22][23].AIDS-related opportunistic infections, neoplasms and HIV infection per se have been hypothesized to predispose patients to a hypercoagulable state [16]. Various other abnormalities in the haemostatic pathways of HIV-infected patients have also been reported [25][26][27].…”

mentioning

confidence: 99%

See 1 more Smart Citation

HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study

et al. 2010

View full text Add to dashboard Cite

ObjectiveThe association between HIV infection and the risk of venous thromboembolism (VTE) is controversial. We examined the risk of VTE in HIV-infected individuals compared with the general population and estimated the impact of low CD4 cell count, highly active antiretroviral therapy (HAART) and injecting drug use (IDU). MethodsWe identified 4333 Danish HIV-infected patients from the Danish HIV Cohort Study and a population-based age-and gender-matched comparison cohort of 43 330 individuals. VTE diagnoses were extracted from the Danish National Hospital Registry. Cumulative incidence curves were constructed for time to first VTE. Incidence rate ratios (IRRs) and impact of low CD4 cell count and HAART were estimated by Cox regression analyses. Analyses were stratified by IDU, adjusted for comorbidity and disaggregated by overall, provoked and unprovoked VTE. ResultsThe 5-year risk of VTE was 8.0% [95% confidence interval (CI) 5.78-10.74%] in IDU HIV-infected patients, 1.5% (95% CI 1.14-1.95%) in non-IDU HIV-infected patients and 0.3% (95% CI 0.29-0.41%) in the population comparison cohort. In non-IDU HIV-infected patients, adjusted IRRs for unprovoked and provoked VTE were 3.42 (95% CI 2.58-4.54) and 5.51 (95% CI 3.29-9.23), respectively, compared with the population comparison cohort. In IDU HIV-infected patients, the adjusted IRRs were 12.66 (95% CI 6.03-26.59) for unprovoked VTE and 9.38 (95% CI 1.61-54.50) for provoked VTE. Low CD4 cell count had a minor impact on these risk estimates, while HAART increased the overall risk (IRR 1.93; 95% CI 1.00-3.72). ConclusionHIV-infected patients are at increased risk of VTE, especially in the IDU population. HAART and possibly low CD4 cell count further increase the risk. DOI: 10.1111/j.1468-1293.00869.x HIV Medicine (2011 r 2010 British HIV Association 202 unrecognized even in modern health care systems [4]. It is important to clarify the main risk factors for VTE in order to identify individuals who may benefit from primary thromboprophylaxis [4,5]. Since the introduction of highly active antiretroviral therapy (HAART), HIV has become a chronic disease and life expectancy has increased substantially [6][7][8]. However, HIV-infected patients still experience considerable longterm treatment-associated morbidity.Recent studies of vascular disease in HIV-infected patients have focused on potential atherosclerotic complications in HAART-exposed patients [9,10]. In contrast, few studies have examined the risk of VTE in HIV-infected patients in the HAART era [11][12][13][14][15][16][17][18]. Studies mainly from the pre-HAART era estimated that the overall risk of VTE in patients with HIV infection was roughly 2-10-fold higher than expected in the general population [11][12][13][14][15][16][17][18][19][20][21][22][23][24]. However, many studies were limited by small sample size [15,16,22,23] and a lack of a population-based comparison cohort [11][12][13]15,16,19,[21][22][23].AIDS-related opportunistic infections, neoplasms and HIV infection per se have been hypothesized...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Thrombotic events of unexplained etiology have been well-documented in HIV-infected patients [10][11][12]. A hypercoagulable state as a result of anticardiolipin antibodies and protein S deficiency, a higher frequency of cytomegalovirus infection in an HIV setting with a propensity of cytomegalovirus to cause intimal proliferation as well as drug therapy, e.g.…”

Section: Discussionmentioning

confidence: 99%

Pyomyositis Associated with Bacillary Angiomatosis in a Patient with HIV Infection

Husain

Singh

2002

Infection

View full text Add to dashboard Cite

Bacillary angiomatosis is an opportunistic infection occurring predominantly in patients with HIV infection. The manifestations of this vasculoproliferative disorder vary markedly. Virtually any organ site may be involved, singly or multiply. However cutaneous involvement can be a valuable clue to its diagnosis. We report a case of bacillary angiomatosis in an HIV-infected patient presenting as isolated pyomyositis of the right leg. The rarity of such a presentation and paucity of cutaneous lesions, as in our case, may render timely diagnosis elusive and difficult. Its recognition however, is important since bacillary angiomatosis, if untreated, is potentially fatal.

show abstract

“…There was, however, no beneficial effect of prophylaxis on mortality due to thromboembolic complications [48]. In chronic viral diseases, such as CMV or HIV infection, the risk of thromboembolic complications is relatively low [49,50].…”

Section: Clinical Aspects Of Hemostasis In Bacterial and Viral Infectmentioning

confidence: 99%

Review: Infectious Diseases and Coagulation Disorders

et al. 1999

View full text Add to dashboard Cite

Infection, both bacterial and nonbacterial, may be associated with coagulation disorders, resulting in disseminated intravascular coagulation and multiorgan failure. In the last few decades a series of in vivo and in vitro studies has provided more insight into the pathogenetic mechanisms and the role of cytokines in these processes. Because of the growing interest in this field, the complexity of the subject, and the fact that many physicians must deal with a variety of infections, current data are reviewed on the association between infectious diseases and the coagulation system. Novel therapeutic intervention strategies that will probably become available in the near future are mentioned, along with those of special interest for infectious disorders for which only supportive care can be given.

show abstract

Venous thrombosis in HIV infection

Cited by 34 publications

References 9 publications

HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study

HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study

Pyomyositis Associated with Bacillary Angiomatosis in a Patient with HIV Infection

Review: Infectious Diseases and Coagulation Disorders

Contact Info

Product

Resources

About